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Objectives. To compare polytetrafluorethylene (PTFE) and polyester grafts (Dacron) for above knee femoropopliteal
bypass.
Design. Multicenter randomised clinical trial.
Material and Methods. 427 patients were randomised between 6 mm Dacron (Uni-Graft, B. Braun Melsungen AG,
34212 Melsungen, Germany) and PTFE (Goretex, W. L. Gore & Ass. Inc., Newark DE 19711, USA) above-knee fem-
oropopliteal bypass grafts within 13 centres in Denmark (n¼ 261), Norway (n¼ 113) & Finland (n¼ 53) between 1993
and 1998. Fourteen (3%) patients were excluded, leaving 413 patients with 208 Dacron and 205 PTFE grafts for analysis.
Age, gender, indication (claudication: 65%), run-off (2 or 3 vessels: 76%), diabetes (17%) and hypertension (31%) as well
as cerebrovascular (9%) and cardiac (33%) risks were evenly distributed. Patients were followed postoperatively at 1, 12
and 24 months. Patency assessment was based on ankle-brachial pressures or imaging in case of doubt.
Results. The two-year primary patency rates for Dacron and PTFE were 70% and 57% (p¼ 0.02), whereas the secondary
patency rates were 76% and 65% (p¼ 0.04), respectively. Primary patency at two years was significantly influenced by
the number of patent crural vessels (two or three 67%, one 50%, p¼ 0.01). Amputations at two years, major in 4% and
minor in 3%, 30-days mortality and complications (wound infections: 3% and other wound complications: 13%) occurred
equally frequent in both groups. At two years, patients treated for critical limb ischemia had a major amputation more often
than patients operated on for intermittent claudication, 10 and 3 respectively (p¼ 0.003), and had higher mortality rates,
20% and 8% respectively (p¼ 0.001).
Conclusion. This trial confirms that Dacron is at least as durable as PTFE for above-knee bypass procedures, and might
even be superior.
Keywords: Dacron; PTFE; Femoro-popliteal bypass; Above-knee; Peripheral bypass; Claudication; Critical ischemia.Introduction
Autologous vein is the preferred graft material for
below-knee and crural bypass procedures.1,2 In the
above-knee position the graft material of choice is
less obvious, though recently published systematic
reviews have concluded that a venous bypass should
be chosen at all times.3,4 In absence of a suitable sa-
phenous vein, or to spare the vein for a future bypass
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tive.5 PTFE handles well and excellent clinical results
have been reported.1,5
For decades, PTFE has been preferred over Dacron
or other prosthetic material, though superiority has
never been shown in randomised clinical trials. In
1993 we initiated a randomised clinical trial to test
the hypothesis that Dacron and PTFE performed
equally well as material for femoropopliteal arterial
above-knee bypass grafts.
Material and Methods
Thirteen departments from different Scandinavian
countries participated (Table 1). The protocol followedrved.
45The Popup Studythe rules of the Helsinki declaration and was ap-
proved by the ethical committees of the participating
centers (Copenhagen & Frederiksberg: Ref 01-312/93).
The protocol was registered at clinicaltrials.gov as
a randomised trial (ID: NCT00300690). Based on 1½
year recruitment period, a two-year patency rate of
75% and accepting a difference of up to 15%, and
a drop-out rate of 10%, it was calculated that the
study needed to include 190 patients in each arm, to
obtain sufficient statistical power (a¼ 0.05 and
b¼ 0.2).
Inclusion and exclusion criteria
The study included all consecutive patients with
chronic lower limb ischaemia, considered suitable
for surgical revascularisation using a supragenicular
prosthetic bypass graft, provided the patients con-
sented to take part. Patients were excluded from the
study, if they were younger than 18 years of age,
were pregnant, had already been enrolled in the
study, were considered impossible to follow or if
informed consent could not be obtained.
Methods
The grafts used were either a 6 mm Uni-graft
(B. BraunMelsungen AG, 34212 Melsungen, Germany),
Table 1. Trial centres participating
Hospital Trial doctor No. of
patients
Denmark
1 Rigshospitalet, Copenhagen Torben V Schroeder
and Leif P Jensen
72
2 Bispebjerg Hospital,
Copenhagen
Ulf Helgstrand 13
3 Gentofte Hospital,
Copenhagen
Niels Bækgaard 15
4 Central Hospital, Hillerød Ole Michael Nielsen 14
5 Odense University Hospital Ole C Røder 43
6 Kolding Hospital Morten Stahl Madsen 36
7 Viborg Hospital Helge Fasting 28
8 Skejby University
Hospital, A˚rhus
Bent Skov Jensen 40
Norway
9 St.Olavs University
Hospital, Trondheim
Hans Olav Myhre
(Jan Lundbom y)
26
10 Akershus University
Hospital , Nordbyhagen
Odd Grenager 29
11 Stavanger Universitetssykehus. Jan Erling Fossdal 50
12 Oppland Hospital, Gjøvik Asle Dahle and
Tor Stuland
8
Finland
13 University Central
Hospital, Helsinki.
Mauri Lepa¨ntalo 53
Total number of patients recruited 427a gelatin-coated, knitted, double velour, polyester
Dacron graft or a 6 mm Gore-Tex (W. L. Gore &
Ass. Inc., Newark DE 19711, USA), made from
expanded PTFE.
All patients had a preoperative arteriography, with
recording of anatomical details of inflow and outflow
arteries. Patient characteristics, risk factors, indica-
tions for surgery and arteriographic findings are
shown in Table 2. Immediately before surgery, the
graft material was selected by a pre-processed sealed
envelope. Randomisation was stratified for each cen-
tre. Surgery was performed as routinely done at
each center, in all cases with end-to-side anastomosis
both proximally and distally. Perioperative antithrom-
botic therapy and antibiotics were administered ac-
cording to the routine of the individual vascular unit.
Endpoints
Primary patency was the primary endpoint. A graft
was considered patent, if the ankle-brachial index
(ABI) remained improved by more than 0.15 com-
pared to the preoperative value, or if graft imaging
by means of arteriography or ultrasonography con-
firmed patency. Imaging was performed when ABI
measurements were considered unreliable or when
there was a concern about patency. In case of graft oc-
clusions between visits, the best estimate of occlusion
time was made from the patient’s history.
Secondary patency, limb survival and complications
were chosen as secondary endpoints. Complications
consisted ofwound complications (haematoma, lymph
oozing), wound infection, other surgical complications
(embolism, nerve injuries etc.) or general complica-
tions (such as cardiopulmonary, stroke, renal etc.)
Postoperative surveillance
The patients were scheduled to follow-up after one
month and one and two years postoperatively. Infor-
mation regarding patency, amputation and complica-
tions were recorded, together with information on
patient survival. If patients had additional follow-up
in the period, information regarding the nature of
the visit was recorded. If the patient dropped out of
the study before the final visit at 24 months, previ-
ously recorded information was included in the calcu-
lations until the time of censoring.
Statistical analysis
Statistical analysis was performed with the Chi-
squared test when comparing results regarding groupEur J Vasc Endovasc Surg Vol 34, July 2007
46 L. P. Jensen et al.Table 2. Comparison of the Dacron and PTFE group, regarding demographics, indication for surgery and risk factors
Total PTFE Dacron p-value
Value % Value % Value %
Patients included 413 205 208
Sex
Female 152 37 69 34 83 40
Male 261 63 136 66 125 60 0.19
Age Mean (Range) years 66 (22e85) 66 (22e85) 66 (30e85)
Risk factors
Cardiac disease 135 33 73 36 62 30 0.21
Cerebrovascular disease 37 9 19 9 18 9 0.83
Hypertension 127 31 63 31 64 31 0.98
Pulmonary disease 68 16 31 15 37 18 0.47
Diabetes 68 16 28 14 40 19 0.13
Self-relianta 361 88 180 88 181 87 0.81
Tobbaco useb 333 59 162 61 171 59 0.79
Previous Vascular Surgery 166 40 89 44 77 37 0.18
Previous Amputation 11 3 7 4 4 2 0.26
Indication for surgery
Claudication 270 65 133 65 137 66 0.83c
Resting pain 72 17 38 19 34 16 0.75d
Ischaemic ulcers 50 12 26 13 24 12
Gangrene 17 4 7 3 10 5
Unknown 4 1 1 0 3 1
Adequate vein 167 41 86 42 81 39 0.51
Mean preoperative ABI 0.52 0.54 0.51
Angiography
Run in
Normal 233 56 113 55 120 58 0.60
Slightly impaired 119 29 60 29 59 28
Severely impaired 58 14 30 15 28 13
Unknown 3 1 2 1 1 0
No. of patent crural arteries
1 94 23 49 24 45 22
2 155 38 79 39 76 37 0.43
3 157 38 74 36 83 40 0.60
Unknown 7 2 3 1 4 2
a Able to manage daily life in own home.
b Present smoker or recently stopped.
c Comparing claudicants with the rest (critical ischaemia).
d Comparing patients with tissue loss with no tissue loss.distribution and Kaplan-Meier analysis and logrank
test when comparing survival data (patency, ampu-
tation-rates and survival-rates). Differences were con-
sidered significant at the level of p< 0.05 (two-sided).
Calculations were performed using the statistical
package STATA, version 8.2.
Results
In all 427 patients were recruited for the study, in the
period from October 1993 to January 1997. One pa-
tient was never properly randomised, leaving 426 pa-
tients to receive either Dacron (216 patients) or PTFE
(210 patients, Fig. 1). 13 patients were excluded, leav-
ing 413 patients for further analysis (Fig. 1).
The two treatment-groups were comparable re-
garding demographic data, indication for surgery,Eur J Vasc Endovasc Surg Vol 34, July 2007arteriographic findings and various risk factors
(Table 2). Most patients were operated on for intermit-
tent claudication. The majority of patients had postop-
erative anti-platelet therapy, whereas anticoagulation
therapy was used only occasionally (Table 3). There
were no differences between treatment groups with
respect to the listed postoperative complications
(Table 3).
At two years 91 patients (22%) were censored, of
which 38 (9%) were deceased, 2 (0.5%) amputated
with unknown graft status and 51 (12%) were lost to
follow-up (Fig. 1).
Primary 2 year graft patency was significantly bet-
ter in patients receiving Dacron as compared to PTFE:
70% (CI: 62e76%) vs. 57% (CI: 49e64%) (logrank test,
p¼ 0.02, Fig. 2). Similar results were seen for second-
ary patency: 76% (CI: 69e81%) vs. 65% (CI: 57e72%)
(logrank test, p¼ 0.04, Fig. 3). Secondary interventions
47The Popup Study427 patients enrolled
1 excluded
(not scheduled for fem-pop bypass)
426 patients randomised
216 Dacron
8 excluded:
3 exclusion criteria's
(1 double randomised, 2 excluded)
4 no postoperative data obtained
1 no valid patient identification
210 ePTFE
5 excluded:
2 exclusion criteria's
(1 no surgery, 1 double randomised)
3 no postoperative data obtained
208 available for analysis 205 available for analysis
24 Patients censored at 1 year
14 deceased, 1 amputated
9 lost to follow-up
50 Patients censored at 2 years (cumulated)
20 deceased, 2 amputated
28 lost to follow-up
24 Patients censored at 1 year
10 deceased, 0 amputated
14 lost to follow-up
41 Patients censored at 2 years (cumulated)
18 deceased, 0 amputated
23 lost to follow-up
Fig. 1. Flowchart of participants in the POPUP study.included graft thrombectomy alone (51%), throm-
bectomy and graft revision (41%) and thrombolysis
(9%). There was a tendency towards better primary
patency at two years for patients operated on for
claudication (patency 65%, CI: 59e71%) compared to
critical ischemia (patency 59%, CI: 49e68%) but it
did not reach statistical significance (Logrank test,
p¼ 0.21). The number of patent crural arteries at
time of operation influenced primary patency at two
years: Patients with more than one outflow vessel
(patency¼ 67%, CI: 61e72%) performed significantlybetter than those with one patent tibial vessel
(patency¼ 50% , CI: 37e61%, Logrank test p¼ 0.01).
Only two major amputations, above the ankle, took
place within 30 days, both in diabetic women, with an
occluded Dacron graft, and operated on for critical is-
chemia with ischemic ulcer and gangrene respectively
(NS). At two years, 13 (3.7%) patients had a major am-
putation of the previously operated limb, of which
seven (3.7%) patients had a Dacron graft and six
(3.7%) patients had a PTFE graft (NS). Of the 13 pa-
tients who had a major amputation, 10 were operatedTable 3. Postoperative treatment and complications
Total PTFE Dacron p-value
Value % Value % Value %
Postoperative treatment
Postoperative antiplatelet therapy 321 82 159 82 162 82 0.92
Postop. oral anticoagulation 12 3 6 3 6 3
Additional procedures 39 9 16 8 23 11 0.26
Mean postoperative ABI 0.77 0.76 0.79
Complications
Wound complicationsa 52 13 30 15 22 11 0.22
Surgical Wound Infection 11 3 6 3 5 3 0.77
Bleedingb 7 2 3 2 4 2 0.79
Cardiac complicationsc 15 4 7 4 8 4 0.83
Pulmonary complicationsd 6 2 4 2 2 1 0.39
30 day major amputatione,f 2 0.5 0 0 2 1.0 0.16
30 day mortalityf 3 0.7 2 1.0 1 0.5 0.56
a Skin necrosis, lymph oozing, haematoma.
b Only surgically treated.
c Myocardial infarction, medically treated arrythmia.
d Pneumonia and atelectasis in need of treatment.
e Crural level or above, whether graft was open or not.
f Estimated by Kaplan-Meier survival analysis at 30 days with logrank test.Eur J Vasc Endovasc Surg Vol 34, July 2007
48 L. P. Jensen et al.on for critical limb ischaemia and three for claudica-
tion (p< 0.001). Minor amputations on toes or forefoot
were only performed in 10 patients, five who had Da-
cron and five that received PTFE grafts. These were all
additional procedures in patients with gangrene of
toes or forefoot.
At two-year 12.3% patients were deceased, 12.4% in
the Dacron-group and 12.1% in the PTFE-group (NS).
The indication for surgery had significant impact
on the two-year mortality-rate, being 8% (CI: 6e12%)
for patients operated on for intermittent claudication
and 20% (CI: 14e28%) for patients with critical limb
ischemia (logrank, p¼ 0.003).
Discussion
Our study supports our initial hypothesis, that Da-
cron and PTFE perform equally well for above-knee
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Fig. 3. Secondary patency.Eur J Vasc Endovasc Surg Vol 34, July 2007femoro-popliteal revascularisation. Dacron might even
be better. At the time this studywas prepared, no rand-
omised controlled trial had been performed to com-
pare PTFE to Dacron in femoro-popliteal prosthetic
bypass. Meanwhile, five randomised trials have been
published comparing Dacron and PTFE6e11 (Table 4).
The first published trial was North American and
randomised 244 patients, all having above-knee
grafts. Neither at 3 nor at 5 years could a difference
be detected.6,7 Two other trials from Australia and
Germany enrolled 108 and 194 patients, respectively.
Both included above as well as below knee proce-
dures, and neither found any statistical difference
between patency in patients receiving PTFE or
Dacron.8,9 The most recent trial from the same
Australian group as above compared fluoropolymer
coated Dacron to PTFE in 129 patients receiving
both above and below knee reconstructions.11 A sig-
nificant difference was reported in primary patency
after two years in favour of PTFE (47%) over Dacron
(36%), whereas the difference in secondary patency
was not significant. Finally, 209 patients e the major-
ity had above-knee femoropopliteal bypass e were
randomised to receive either Heparin-bonded Dacron
or PTFE.10 The authors of this trial reported signifi-
cantly better results with Dacron as compared with
PTFE after 3 years. After 5 years there was no signif-
icant difference in graft patency, but there was a
significant higher rate of major amputations in the
PTFE-group.
Though a formal meta-analysis was not performed,
the general impression from the existing trials is clear:
Dacron is not inferior to PTFE, when used for femoro-
popliteal revascularisation.12 Our study, being the
largest randomised trial on the subject until now, indi-
cated that Dacron grafts performed better. It may
therefore be questioned whether PTFE should con-
tinue to be the favoured prosthetic graft material for
above-knee reconstructions. Also from an economical
point of view, the current practice can be questioned,
as Dacron grafts in most countries are less expensive
than PTFE.
One factor also to be taken into consideration is the
continuous improvement in vascular graft technology.
Since our study took place, new variations of PTFE
and Dacron grafts have been introduced into the mar-
ket, with different coatings, e.g. Heparin. These mod-
ifications of known prostheses might alter the
properties of the grafts to an extent, that results
from trials on older types no longer can be applied
fully to the current situation.13 In conclusion, how-
ever, so far there is no evidence to support the opin-
ion, that PTFE in it self performs superior to Dacron
in the clinical setting.
49The Popup StudyTable 4. Main results from existing randomised controlled trials on femoropopliteal bypass comparing PTFE with Dacron
No. pts. Above Knee % Follow-up
time (years)
Primary patency Secondary patency
PTFE Dacron PTFE Dacron
Abbot et al. 19985 244 100 3 58 62 75 75
Green et al. 20006 5 43 45 68 68
Robinson et al. 19997 108 69 3 52 47 54 53
Post et al. 20018 194 73 3 61 64 75 81
Devine et al. 2004* 9 209 86 3 42 55 45 56
5 35 46 36 47
Robinson et al. 200310 129 59 2 47 36 48 46
Present series 2006 416 100 2 57 70 65 76
* Compared heparin bonded Dacron with PTFE.Acknowledgements
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